TNFRSF4 and hypoparathyroidism-retardation-dysmorphism syndrome: For HRD tumors, we suggest the combined administration of anti‐CCR8/CTLA‐4 or TNFRSF4 stimulator targeting Tregs and ICB (anti‐PDCD1/CTLA4/LAG‐3/TIGIT) to restore the activity of CXCL13+CD8+ Tex cells.